Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma

BACKGROUND: A phase II randomised discontinuation trial assessed cabozantinib (XL184), an orally bioavailable inhibitor of tyrosine kinases including VEGF receptors, MET, and AXL, in a cohort of patients with metastatic melanoma. METHODS: Patients received cabozantinib 100 mg daily during a 12-week...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Br J Cancer
मुख्य लेखकों: Daud, Adil, Kluger, Harriet M, Kurzrock, Razelle, Schimmoller, Frauke, Weitzman, Aaron L, Samuel, Thomas A, Moussa, Ali H, Gordon, Michael S, Shapiro, Geoffrey I
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Nature Publishing Group 2017
विषय:
Clinical Study
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5318966/
https://ncbi.nlm.nih.gov/pubmed/28103611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.419
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन